文献速递治疗药物监测与药物基因组学抗栓抗凝管理

大型农村医疗中心预防性华法林药物基因组学检测的初步结局

Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

该研究在大型农村医疗系统内对749例患者进行VKORC1和CYP2C9基因分型,其中27例被处方华法林并收到药物基因组学警报。20例达到目标INR 2.0-3.0,65%在警报推荐剂量±0.5 mg/天内达标;10例初治患者中,警报推荐剂量组达到首次稳定目标INR的时间趋势更快(34±28天 vs 129±117天),未发现出血、血栓栓塞、住院或死亡的趋势。

要点

  • 预防性药物基因组学检测可为华法林处方提供基因型指导的剂量警报。
  • 多数收到警报的患者在推荐剂量±0.5 mg/天内达到目标INR。
  • 初治患者按警报推荐剂量起始可能更快达到稳定目标INR。

核心结论

  • 在抗凝监测项目中将药物基因组学检测作为标准服务可能改善抗凝治疗患者的剂量方案。

研究设计与样本

  • 对大型农村医疗系统中接受预防性药物基因组学检测和华法林剂量的患者进行监测至2017年6月。
  • 20个月期间,749例患者作为eMERGE PGx研究的一部分接受VKORC1和CYP2C9基因分型。

主要发现

  • 27例被处方华法林并收到与华法林相关的药物基因组学警报。
  • 20例达到目标INR 2.0-3.0,其中65%在警报推荐剂量±0.5 mg/天内达到目标剂量。
  • 10例初治患者中,警报推荐剂量组达到首次稳定目标INR的平均时间为34±28天,警报外剂量组为129±117天。
  • 未发现出血、血栓栓塞事件、住院或死亡率与药物基因组学警报相关的趋势。

关键数值与推荐

  • 药物基因组学警报为处方医生提供药物基因组学剂量信息,并似乎能根据患者基因型适当地部署正确推荐。

临床怎么用

  • 在抗凝监测项目中实施药物基因组学检测作为标准服务,可能为华法林治疗患者提供基因型指导的剂量推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As a preliminary evaluation of the outcomes of implementing pharmacogenetic testing within a large rural healthcare system, patients who received pre-emptive pharmacogenetic testing and warfarin dosing were monitored until June 2017. SUMMARY: Over a 20-month period, 749 patients were genotyped for VKORC1 and CYP2C9 as part of the electronic Medical Records and Genomics Pharmacogenetics (eMERGE PGx) study. Of these, 27 were prescribed warfarin and received an alert for pharmacogenetic testing pertinent to warfarin; 20 patients achieved their target international normalized ratio (INR) of 2.0-3.0, and 65% of these patients achieved target dosing within the recommended pharmacogenetic alert dose (± 0.5 mg/day). Of these, 10 patients had never been on warfarin prior to the alert and were further evaluated with regard to time to first stable target INR, bleeds and thromboembolic events, hospitalizations, and mortality. There was a general trend of faster time to first stable target INR when the patient was initiated at a warfarin dose within the alert recommendation versus a dose outside of the alert recommendation with a mean (± SD) of 34 (± 28) days versus 129 (± 117) days, respectively. No trends regarding bleeds, thromboembolic events, hospitalization, or mortality were identified with respect to the pharmacogenetic alert. The pharmacogenetic alert provided pharmacogenetic dosing information to prescribing clinicians and appeared to deploy appropriately with the correct recommendation based upon patient genotype. CONCLUSION: Implementing pharmacogenetic testing as a standard of care service in anticoagulation monitoring programs may improve dosage regimens for patients on anticoagulation therapy.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Leary E, Brilliant M, Peissig P, et al. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center. Am J Health Syst Pharm. 2019. PMID: 31415684. doi:10.1093/ajhp/zxy072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。